Mode
Text Size
Log in / Sign up

Heart Failure with Preserved Ejection Fraction

Part of Heart Failure

15 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Heart Failure with Preserved Ejection Fraction

23 trials tracked for Heart Failure with Preserved Ejection Fraction: 11 in phase 3 or 4 and 8 with published results. The most-cited published study has 166 citations.

23Trials tracked
11Phase 3 & 4
0Recruiting
8With published results
Phase distribution
Phase 4 4 Phase 3 7 Phase 2 9 Phase 1 1 Other / NA 2
  1. Phase 3 A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients Completed · 166 cited
  2. Phase 3 A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial Completed · 163 cited
  3. Phase 3 Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction Completed · 107 cited
  4. Phase 3 DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction Completed · 56 cited
  5. Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40% Completed · 45 cited
  6. Phase 3 Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF) Completed · 29 cited
Show 17 more trials
  1. Phase 3 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. Completed · 14 cited
  2. Phase 4 BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF Completed
  3. Phase 4 Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction Completed
  4. Phase 4 Impact of Beta-blockers on Physical Function in HFpEF Completed
  5. Phase 4 Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF Completed
  6. Phase 2 Study of Verinurad in Heart Failure With Preserved Ejection Fraction Completed
  7. Phase 2 Developing Oral LT3 Therapy for Heart Failure - HFpEF Completed
  8. Phase 2 Cilostazol for HFpEF Completed
  9. Phase 2 Acute Effects of Exogenous Ketone Ester Administration in Heart Failure Completed
  10. Phase 2 A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease Completed
  11. Phase 2 A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT Completed
  12. Phase 2 Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction Completed
  13. Phase 2 A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Completed
  14. Phase 2 Dapagliflozin (DAPA) Effects in HFpEF Completed
  15. Phase 1 Pressure Assessment to Improve Outcomes After TAVR: a Registry Completed
  16. N/A The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction Completed
  17. N/A Heart Function in Patients Assessed for Sleep Apnoea Completed

Showing the 23 most-cited and recently-updated of 23 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Heart Failure with Preserved Ejection Fraction: what the trials found

New evidence indicates that Amlodipine Besylate significantly reduces home systolic blood pressure in patients with Heart Failure with Preserved Ejection Fraction (HFpEF) 1. However, it did not show a statistically significant effect on home diastolic or office systolic blood pressure 1.

Tirzepatide demonstrated significant clinical benefits in HFpEF, including a reduction in the first occurrence of heart failure outcomes (p=0.026), improved exercise capacity as measured by 6-minute walk distance (p<0.001), and a significant reduction in body weight 6.

Sacubitril/valsartan was shown to significantly reduce NT-proBNP levels at week 12 5 and week 8 10. In a large trial, LCZ696 showed a significant improvement in NYHA functional class at month 8 7.

Dapagliflozin demonstrated significant improvements in physiological markers including reduced pulmonary capillary wedge pressure (PCWP) at both rest and maximal exercise, as well as weight loss 16. In a large-scale trial, Dapagliflozin significantly reduced the composite endpoint of cardiovascular death or heart failure hospitalization/urgent visits 11.

Recent results — preliminary, needs further review

  • mavacamten showed a reduction in NT-proBNP and high-sensitivity cardiac troponin T levels at week 26 (not yet corroborated)
  • Nitrite was associated with lower exercise pulmonary capillary wedge pressure and changes in central pressures (not yet corroborated)

For the clinician treating this condition

  • Amlodipine Besylate may be utilized for blood pressure management specifically targeting systolic pressure in HFpEF patients.
  • Tirzepatide is associated with significant weight loss and improved exercise capacity in the HFpEF population.
  • Sacubitril/valsartan (LCZ696) effectively reduces NT-proBNP levels and improves NYHA functional classification.
  • Dapagliflozin provides evidence of reduced heart failure hospitalizations and improvements in pulmonary wedge pressures.

AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Heart Failure

Related studies from across the Heart Failure family.

Intradialytic exercise improves cardiovascular function and arterial stiffness in patients on maintenance haemodialysis
Physical Medicine & Rehab Meta-analysis
Intradialytic exercise improves cardiovascular function and arterial stiffness in patients on maintenance haemodialysis Intradialytic Exercise May Improve Heart Function in Dialysis Patients
This meta-analysis of 934 patients receiving maintenance haemodialysis found that intradialytic exercise improved left ventricular ejection …
Exercise during dialysis may improve heart function and blood pressure for patients with heart failure on maintenance hemodialysis.
Four mailer types aim to increase health care proxy documentation in patients with chronic conditions
Primary Care & Family Medicine RCT
Four mailer types aim to increase health care proxy documentation in patients with chronic conditions New trial plans to use mailers to help patients name proxies
This study protocol describes a factorial randomized trial of approximately 20,000 patients with cancer, congestive heart failure, or chroni…
A new study plans to see if different types of mailers can help patients with serious illnesses name a healthcare proxy.
Rheumatic heart disease prevalence in Nepal is 3.1% with significant geographic and temporal disparities
Cardiology Meta-analysis
Rheumatic heart disease prevalence in Nepal is 3.1% with significant geographic and temporal disparities Rheumatic heart disease is much more common in rural Nepal
This meta-analysis of 209,815 participants in Nepal indicates a pooled rheumatic heart disease prevalence of 3.1%. Findings show a higher pr…
New data shows rheumatic heart disease is six times more common in rural areas of Nepal compared to the capital city of Kathmandu.
High-flow nasal cannula shows no significant difference from noninvasive ventilation in acute heart failure
Rheumatology Meta-analysis
High-flow nasal cannula shows no significant difference from noninvasive ventilation in acute heart failure High-flow nasal cannula shows no advantage over noninvasive ventilation
This meta-analysis of 1,282 patients with respiratory failure secondary to acute heart failure found no statistically significant difference…
New data shows that high-flow nasal cannula does not outperform noninvasive ventilation for patients with heart failure and respiratory issu…
Geographic and socioeconomic disparities limit access to mechanical circulatory support and heart transplantation
Cardiology Sys. Review
Geographic and socioeconomic disparities limit access to mechanical circulatory support and heart transplantation Heart Devices and Transplants Are Out of Reach for Many
This narrative review with scoping methods examines the global landscape of mechanical circulatory support (MCS) and heart transplantation f…
A new review finds heart transplants and mechanical support are concentrated in wealthy regions, leaving many patients without access.
Breviscapine Add-On May Improve Angina Response in Coronary Heart Disease
Cardiology Meta-analysis
Breviscapine Add-On May Improve Angina Response in Coronary Heart Disease Breviscapine May Help Heart Disease Patients With Angina Symptoms
A meta-analysis finds breviscapine plus conventional therapy improves total effective rate in coronary heart disease with angina. Safety dat…
A new analysis finds breviscapine may improve treatment success for people with heart disease and angina. More research is needed to confirm…
Conduction system pacing reduces heart failure hospitalization and cardiomyopathy risk compared to right ventricular pacing
Cardiology Meta-analysis
Conduction system pacing reduces heart failure hospitalization and cardiomyopathy risk compared to right ventricular pacing Conduction system pacing may lower heart failure hospital risks
This meta-analysis of randomized controlled trials involving 1466 patients with preserved or mildly reduced LVEF found that conduction syste…
A new type of heart pacing could significantly lower the risk of heart muscle damage and hospital stays for patients with heart failure.
Culturally tailored meal programs reduce hospitalization rates among patients with heart failure
Cardiology RCT
Culturally tailored meal programs reduce hospitalization rates among patients with heart failure Tailored Navajo meal program reduces heart failure hospital visits
Researchers evaluated a culturally and medically tailored meal program for adults with heart failure in a rural setting. The intervention wa…
A culturally tailored meal program using traditional Navajo foods helped reduce hospital visits for patients living with heart failure.
Disulfidptosis may drive cardiomyocyte injury and cytoskeletal collapse under conditions of disulfide stress
Cardiology Sys. Review
Disulfidptosis may drive cardiomyocyte injury and cytoskeletal collapse under conditions of disulfide stress New research explores a specific cell death path in heart failure
This narrative review explores the role of disulfidptosis in heart failure and cardiomyocyte injury. The authors suggest that disulfide stre…
Scientists are looking into a process called disulfidptosis to understand how heart cells die during heart failure.
Sarcopenia and Low Grip Strength Correlate with Increased Cardiovascular Risk in Older Adults
Geriatrics & Aging Meta-analysis
Sarcopenia and Low Grip Strength Correlate with Increased Cardiovascular Risk in Older Adults Low Muscle Mass and Grip Strength Linked to Heart Risks
A large-scale meta-analysis identifies sarcopenia and low grip strength as significant markers for increased cardiovascular events in elderl…
Lower muscle mass and weaker grip strength are linked to a higher risk of heart disease and stroke in older adults.
Tai Chi provides positive effects for balance, mood, and cognitive performance in older adults
Primary Care & Family Medicine Guideline
Tai Chi provides positive effects for balance, mood, and cognitive performance in older adults Tai Chi Shows Positive Effects for Older Adults with Parkinson's
This evidence map synthesized 118 systematic reviews regarding Tai Chi for older adults. The findings indicate positive effects for balance,…
Tai Chi may help older adults improve balance, reduce anxiety, and manage symptoms of Parkinson's disease and other age-related conditions.
Semaglutide reduces NT-proBNP levels and heart-failure hospitalization in adults with HFpEF and obesity
Nutrition & Obesity Medicine Meta-analysis
Semaglutide reduces NT-proBNP levels and heart-failure hospitalization in adults with HFpEF and obesity Semaglutide shows promise for heart failure and obesity patients
This meta-analysis of 6 randomized trials involving 4216 adults with HFpEF and obesity found that semaglutide significantly reduced NT-proBN…
A new look at clinical data shows semaglutide may improve symptoms and lower hospital risks for people with obesity and heart failure.

Questions about Heart Failure with Preserved Ejection Fraction

Do GLP-1 drugs and SGLT2 inhibitors reduce hospital visits for my heart failure?

Yes, both GLP-1 receptor agonists and SGLT2 inhibitors reduce hospital visits for heart failure with preserved ejection fraction (HFpEF), according to a large network meta-analysis and other studies.

Full answer →
Does spironolactone lower my risk of heart problems if I have a large heart?

Yes, spironolactone may lower your risk of heart problems if you have a large heart, especially reducing heart failure hospitalizations and cardiovascular death.

Full answer →